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ABSTRACT
Introduction. As estimated by IDF, by 2045 there will 
be about 628 million of people living with diabetes, 
of which 87–91% will have type 2 diabetes. Therefore, 
early diagnosis of diabetes is very important, and cur-
rently only 4–50% of cases are diagnosed early enough. 
The aim of the study was to establish whether patients 
with dyspepsia may potentially be a group at high risk 
of developing diabetes in which screening for glucose 
metabolism disorders would be particularly important.
Material and methods. The study included 59 women 
(65.5%) and 31 men (34.5%), with a mean age of 36 
years, hospitalized in order to perform gastroscopy due 
to symptoms of dyspepsia. All patients were apparently 
healthy, without the history of cardiovascular diseases 
or diabetes, and were non-smokers. The patients were 
subjected to laboratory tests (random blood glucose, 
oral glucose tolerance test [OGTT], lipid profile, C-reac-
tive protein level), gastroscopy and a rapid urease test 
for detection of active Helicobacter pylori infection. 
Body mass index (BMI) was also calculated. Subjects 
with abnormal results of the oral glucose tolerance 
test (OGTT) were assigned to the group with glucose 
metabolism disorders and the remaining subjects — 
to the group without glucose metabolism disorders. 
Statistical analysis of the obtained research results 
was carried out using the Statistica 7.0 PL software.
Results. The subjects were divided into two subgroups 
based on the result of the oral glucose tolerance test, 
adopting the principles of diagnosing carbohydrate 
metabolism disorders according to the Diabetes Po-
land. The group with glucose metabolism disorders 
included 33 patients (36.5%): 5 subjects (5.5%) with 
impaired fasting glucose, 20 patients (22%) with 
impaired glucose tolerance and 8 patients (9%) with 
diabetes. The remaining 57 (63.5%) patients had nor-
mal results of OGTT and were assigned to the group 
without glucose metabolism disorders. The mean BMI 
in the whole examined population was 26.7 kg/m2. 
Patients with glucose metabolism disorders (GMD) had 
a significantly higher BMI (31.1 kg/m2). The levels of 
total cholesterol, LDL cholesterol and TG were higher 
in patients with GDM; however, the difference was not 
statistically significant. Random blood glucose values 
were significantly higher in the group with GDM, but 
no patient had random blood glucose ≥ 200 mg/dL. 
The HbA1c value was significantly higher in the GMD 
group. Also, the C-reactive protein (CRP) level was 
significantly higher in the group of patients with GMD 
than in the group of healthy subjects. All patients un-
derwent gastroscopy and abnormal results were found 
in 41 patients (45.5% of total study population) — in 
67% in the group with GMD and 33% in the group 
without GDM. The most frequent pathology was Heli-
cobacter pylori infection (25.5%). This infection was 
more prevalent in the group with GDM (45%) than in 
the group without GDM (14%). In addition, gastritis, 
gastric cancer, gastro-esophageal reflux, hiatal hernia, 
and gastric polyps were found, without significant 
differences between the subgroups.
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Conclusions. Over 1/3 of the subjects with dyspepsia 
had prediabetes or diabetes; therefore, it seems that 
this group of patients should be screened for glucose 
metabolism disorders. High prevalence of GMD among 
patients with dyspepsia indicates potential benefits of 
performing OGTT in this group of patients. Gastroin-
testinal symptoms may be an early manifestation of 
glucose metabolism disorders. There is a correlation 
between Helicobacter pylori infection and the pres-
ence of glucose metabolism disorders. (Clin Diabetol 
2018; 7, 6: 253–258)
Key words: type 2 diabetes, glucose metabolism 
disorders, dyspepsia
Introduction
Type 2 diabetes is considered as a social disease 
and its prevalence is constantly growing. It is estimated 
that in 2045 there will be about 628 million people with 
diabetes. Currently, only 40–50% of cases are properly 
diagnosed, which enables the implementation of ef-
fective treatment. In the remaining 50–60% diabetes is 
undiagnosed, which — despite the oligosymptomatic 
course — leads to gradual development of complica-
tions. Due to the often asymptomatic course of the 
early stages of type 2 diabetes, screening is of key 
importance for early diagnosis, especially in groups of 
patients at increased risk of carbohydrate disorders.
Dyspeptic symptoms are very common. Recent 
studies show that dyspepsia is more prevalent in 
patients with diabetes than in non-diabetic subjects. 
Therefore, it has been hypothesized that the presence 
of dyspeptic symptoms could be useful in identifying 
a group of patients with higher risk of asymptomatic 
glucose metabolism disorders, including prediabetes. 
Screening these patients for glucose metabolism dis-
orders may result in early diagnosis and consequently 
early implementation of treatment, thus protecting 
patients from silent complications of diabetes and 
even diabetes itself.
The aim of the study was to establish whether 
patients with dyspepsia may potentially be a group 
at high risk of developing diabetes in which screening 
for glucose metabolism disorders would be particularly 
important.
Material and methods
The study included 90 people, 59 women (65.5%) 
and 31 men (34.5%), with an mean age of 36 years, 
hospitalized in the 2nd Department of Cardiology and 
Internal Diseases of the University Clinical Hospital in 
Olsztyn in order to perform gastroscopy due to symp-
toms of dyspepsia. Included in the study were appar-
ently healthy patients, without the history of cardio-
vascular diseases or diabetes, and were non-smokers.
Dyspepsia was defined as the presence of at least 
1 of the following symptoms: epigastric pain, feeling 
of fullness, epigastric discomfort, and eructation [1]. 
The examined patients had the symptoms of dyspepsia 
for at least 3 months. All patients underwent physical 
examination including blood pressure measurement 
and the calculation of the body mass index (BMI), ac-
cording to the Quetelet formula, where BMI = body 
weight [kg]/height [m2].
Following laboratory tests were performed in each 
patient:
 — glycemic profile:
• glycated hemoglobin (HbA1c),
• blood glucose at admission (random), 
• blood glucose on fasting state and 2 hours 
after administration of 75 g glucose (oral 
glucose tolerance test, OGTT). On the basis 
of OGTT, the following glucose metabolism 
disorders (GMD) were diagnosed:
1) impaired fasting glucose (IFG),
2) impaired glucose tolerance (IGT),
3) diabetes mellitus (DM),
 — lipid profile: total cholesterol, LDL cholesterol, 
HDL cholesterol, triglycerides;
 — C-reactive protein (CRP).
All laboratory tests were performed using standard 
methods.
Gastroscopy was carried out using Olympus GIF-Q165 
and GIF-Q180 apparatus, by a qualified endoscopist, 
certified in panendoscopy by the Polish Society of 
Gastroenterology.
A rapid urease test was used to diagnose Helico-
bacter pylori infection.
The study was approved by the Bioethical Com-
mittee of the Warmia and Mazury Regional Medical 
Chamber in Olsztyn on 4th December 2012. It included 
analysis of results of standard diagnostic test and vol-
untary and anonymous surveys.
Statistical analysis
Statistical analysis of the test results was carried out 
using the Statistica 7.0 PL software. To verify hypotheses 
about the existence or absence of relationship between 
categorized variables, the Pearson 2 test and 2 NW test 
(the highest reliability) were used. To compare the mean 
values of measurable variables, the Student’s t-test or 
the nonparametric Mann-Whitney U test were used (for 
comparisons between two groups). The Chi-square test 
was used to compare the qualitative variables using 
cross-tabulation table. The Schapiro-Wilk test was used 
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to analyze measurable variables that were non-normally 
distributed. 95% confidence intervals (95% CI) were 
determined for the analyzed values. P-values < 0.05 
were considered as statistically significant.
Results
The study included 90 people with a mean age 
of 36.1 ± 12.5 years (59 women [65.5%] and 31 men 
[34.5%], hospitalized in the 2nd Department of Car-
diology and Internal Diseases of the University Clinical 
Hospital in Olsztyn due to dyspepsia.
The subjects were divided into two subgroups 
based on the result of the oral glucose tolerance test 
(OGTT), adopting the principles of diagnosing carbohy-
drate metabolism disorders according to the Diabetes 
Poland. The group with glucose metabolism disorders 
included 33 patients (36.5%): 5 subjects (5.5%) with im-
paired fasting glucose, 20 patients (22%) with impaired 
glucose tolerance and 8 patients (9 %) with diabetes. 
The remaining 57 (63.5%) patients had normal results 
of OGTT and were assigned to the group without glu-
cose metabolism disorders (Figure 1).
The mean BMI in the whole examined population 
was 26.7 kg/m2. Patients with glucose metabolism disor-
ders (GMD) had a significantly higher BMI (31.1 kg/m2) 
compared to those without GDM (24.1 kg/m2); 
p = 0.007. The levels of total cholesterol, LDL cholester-
ol and TG were higher in patients with GDM; however, 
the difference was not statistically significant Table 1).
Random blood glucose values were significantly 
higher in the group with GDM than in healthy subjects 
(86.9 mg/dL vs. 93.03 mg/dL, respectively; p < 0.017). 
No patient had random blood glucose ≥ 200 mg/dL.
The HbA1c value was significantly (p < 0.024) high-
er in the GMD group and amounted to 5.5% (Figure 2).
In the group of patients with GMD C-reactive pro-
tein (CRP) level was 1.3 mg/L — significantly (p < 0.003) 
higher than in the group without GDM (Figure 3). 
Table 1. General characteristics of the examined group according to presence of absence (healthy subjects) of glucose 
metabolism disorders (GMD)
Parameter Study groups n (%)
Total 90 (100%) Healthy subjects  
57 (63%)
GMD 33 (37%) p
Age [years, SD] 36.1 ± 12.5 35.2 ± 12.5 37.7 ± 12.6 0.367
BMI [kg/m2] [SD] 26.7 ± 8.3 24.1 ± 4.6 31.1 ± 11.1 0.007
Total cholesterol [mg/dl] [SD] 189.1 ± 42.0 184.2 ± 42.0 197.4 ± 41.3 0.154
LDL cholesterol [mg/dl] [SD] 107.9 ± 32.1 105.9 ± 31.3 111.3 ± 33.7 0.445
HDL cholesterol [mg/dl] [SD] 55,0 ± 15.4 55.7 ± 14.3 53.9 ± 17.4 0.59
Triglycerides [mg/dl] [SD] 109.8 ± 57.9 97.6 ± 43.1 130.7 ± 73.3 0.069
Random glycemia [mg/dl] [SD] 89.2 ± 11.7 86.9 ± 11.4 93.0 ± 11.5 0.017
Fasting glycemia [mg/dl] [SD] 90.2 ± 14.2 86.4 ± 10.0 96.7 ± 17.7 0.000
Glycemia 120 min post-load [mg/dl] [SD] 130.7 ± 45.9 106.5 ± 20.63 172.6 ± 47.6 0.000
HbA1c (%) 5.4 ± 0.6 5.3 ± 0.4 5.6 ± 0.5 0.005
CRP [mg/l; SD] 2.2 ± 3.2 1.3 ± 1.7 3.7 ± 4.4 0.003
SD — standard deviation; BMI — body mass index; CRP — C-reactive protein
Figure 1. The prevalence of glucose metabolism disorders in 
patients with dyspepsia. According to the Diabetes Poland 
guidelines: random blood glucose ≥ 200 mg/dL (≥ 11.1 
mmol/L), measured at the time when symptoms of hyper-
glycemia are presented — diabetes mellitus (DM); fasting 
blood glucose: 70–99 mg/dL — normal fasting blood glucose, 
100–125 mg/dL — impaired fasting glucose (IFG), ≥ 126 mg/dL 
on two occasions — DM; blood glucose at 120 minutes of 
oral glucose tolerance test (OGTT): < 140 mg/dL — normal 
glucose tolerance (NGT), 140–199 mg/dL — impaired glucose 
tolerance (IGT), ≥ 200 mg/dL (11.1 mmol/l) — DM [20]. IFG — 
impaired fasting glucose; IGT — impaired glucose tolerance; 
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All patients underwent gastroscopy and abnormal 
results were found in 41 patients (45.5% of total study 
population) — in 67% in the group with GMD and 33% 
in the group without GDM. The most frequent patho-
logy was Helicobacter pylori infection (25.5%). This 
infection was more prevalent in the group with GDM 
(45%) than in the group without GDM (14%). In addi-
tion, gastritis, gastric cancer, gastro-esophageal reflux, 
hiatal hernia, and gastric polyps were found, without 
significant differences between the subgroups (Table 2).
Discussion
The aim of presented study was to assess the 
prevalence of glucose metabolism disorders (GMD) in 
patients with dyspepsia. Glucose metabolism disor-
ders were diagnosed in 36.5% of patients — impaired 
fasting glucose in 5.5%, impaired glucose tolerance in 
22% and type 2 diabetes in 9% of patients. Accord-
ing to IDF from 2017, 8.8% of the world’s population 
suffers from diabetes, of whom 87–91% have type 2 
diabetes [2]. In Poland, the prevalence of diabetes is 
on average 3.5% [1]. 
The results of our study indicate that the prevalence 
of glucose metabolism disorders among people with 
dyspepsia who consider themselves healthy is surpris-
ingly high. This means that in patients with dyspepsia, 
diagnostic tests for diabetes should be considered. It 
should be emphasized that, although patients with 
GMD had higher mean values of random blood glucose, 
this value did not exceed the normal value, which did 
not allow for identifying GDM patients at this stage of 
the study. Only in 5.5% of people with GMD, fasting 
Figure 3. Mean CRP level in patients with glucose metabolism 
disorders (GMD) and in subjects with normal blood glucose. 
In the GMD group, mean CRP level was 1.3 mg/L, which was 


















Mean ± standard error



















Mean ± standard error
Mean ± 1.96*standard error
Figure 2. Mean HbA1c values in patients with glucose me-
tabolism disorders (GMD) and in subjects with normal blood 
glucose. Mean HbA1c was significantly higher (p < 0.024) in 
the GMD group and was 5.5%
Table 2. The results of gastroscopy in the examined group according to the presence or absence (healthy subjects) of 
glucose metabolic disorders
Pathology Total (n, %) Healthy subjects (n, %) Patients with GMD (n, %) p
Helicobacter pylori 23 (25.5) 8 (14) 15 (45.5) 0.001
Gastritis 8 (9) 4 (7) 4 (12) 0.412
Gastric cancer 1 (1) 0 (0) 1 (3) 0.186
Gastro-esophageal reflux 3 (3) 3 (5) 0 (0) 0.180
Hiatal hernia 5 (5.5) 3 (5) 2 (6) 0.873
Gastric polyp 1 (1) 1 (1.7) 0 (0) 0.444
Total 41 (45.5) 19 (33) 22 (67) 0.002
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blood glucose was abnormal. It was only the OGTT re-
sult that made it possible to detect patients with GMD. 
This observation confirms previous suggestions 
of many authors that patients should be screened for 
glucose metabolism disorders [3] and that the diagnosis 
should be based on OGTT results, not only on random 
blood glucose or fasting blood glucose, as their results 
may remain normal in patients with GMD [4]. 
In the examined population, pathological findings 
in gastroscopy, such as Helicobacter pylori infection, 
gastro-esophageal reflux, gastric cancer, gastoenteri-
tis, hiatal hernia, were observed in 45.5% of patients. 
Taking into account only the group with GDM, these 
abnormalities were found in 66.5% of patients. How-
ever, when considering only organic lesions (excluding 
Helicobacter pylori infection), abnormal results were 
found only in 21%. Therefore, it should be noted 
that dyspepsia is mainly functional in nature and that 
Helicobacter pylori infection is highly prevalent (it was 
diagnosed in as many as 45.5% of patients with GMD). 
In the literature, the relationship between Helicobacter 
pylori infection and the occurrence of metabolic syn-
drome has been described [5]. In a Chinese study [6], 
patients infected with Helicobacter pylori were charac-
terized by a higher level of fasting blood glucose and 
higher BMI. Awareness of this correlation is particularly 
important, considering a study conducted by Mokhtare 
et al. who observed that effective eradication of Helico-
bacter pylori infection resulted in a reduction in fasting 
blood glucose and HbA1c, improvement in lipid profile 
and reduction in waist circumference [7]. It means that 
thanks to the treatment of Helicobacter pylori infection, 
there is a potential chance of improving the prognosis 
in a large group of patients participating in our study. 
According to the authors’ knowledge, the preva-
lence of GMD among patients with dyspepsia has 
not been assessed previously, and the problem of 
prevalence of dyspeptic disorders among patients with 
diabetes is widely discussed in the literature [8–10]. In 
our study, only 4.5% of diabetic patients had abnormal 
results of gastroscopy (except for Helicobacter pylori 
infection). This observation is similar to the results of 
other studies in which dyspepsia has been found to be 
predominantly functional in diabetes, and long-term 
poor metabolic control in diabetes leads to the devel-
opment of gastroparesis [8, 9, 11]. Osicipenko et al. 
showed that dyspepsia affects up to 71% of patients 
with type 2 diabetes, and in 42%, organic changes in 
the digestive tract were confirmed [8]. Dyspepsia was 
correlated with the duration of diabetes and the pres-
ence of other complications. In the study of Marizy 
Faria et al., the relationship between type 1 diabetes 
and dyspepsia was examined. Also in this study, endo-
scopic examination of the upper gastrointestinal tract 
revealed organic changes in 34% of patients. In addi-
tion, as in our study, the association of dyspepsia with 
higher levels of HbA1c was observed: in the group with 
GMD, HbA1c was significantly higher than in the group 
without GDM. The authors also link the occurrence of 
dyspepsia symptoms with worse glycemic control in 
the majority of patients [9, 10]. 
Another interesting relationship revealed by our 
study is the significant association of higher CRP and 
obesity with GMD occurrence. Patients with GMD 
had a significantly higher CRP level and a high BMI 
index. Similar correlations were found in a study by 
Christina et al. [12] who observed a significant rela-
tionship between hsCRP and the risk of developing 
diabetes: elevated hsCRP increased by 40–50% the risk 
of developing diabetes within 15 years of follow-up. 
Also in the Atherosclerosis Risk in Communities (ARIC) 
study, inflammation was strongly correlated with the 
development of diabetes regardless of other factors, 
including obesity [13]. Obesity is a recognized risk 
factor for the development of type 2 diabetes. In the 
ARIC study mentioned above, obese patients had a 
6-fold higher risk of developing diabetes. However, the 
mechanisms responsible for this phenomenon are not 
fully explained [14]. The relationship between obesity 
and elevated inflammatory parameters is so strong 
that obesity is considered a pro-inflammatory factor 
[12, 15]. Numerous reports indicate that inflammation 
caused by obesity may be a link between obesity and 
the development of diabetes [13, 16, 17]. Hotamisligil 
was the first author who proposed this hypothesis, al-
ready in 1994 [18]. It is suggested that obesity leads to 
changes in the expression of some genes in adipocytes, 
which makes them produce many pro-inflammatory 
cytokines [15]. Inflammation causing and enhancing 
oxidative stress leads to dysfunction of pancreatic 
beta-cells [16]. Also the importance of reduced levels of 
adiponectin [17] — a factor that reduces inflammation 
and increases insulin sensitivity of tissues — in obesity 
is emphasized [19]. Moreover, the results of our study 
confirm the existence of association between glucose 
metabolism disorders and obesity, and an additional 
link intensifying these unfavorable relationships may be 
co-existing Helicobacter pylori infection, being another 
pro-inflammatory factor.
Conclusions
Over 1/3 of the subjects with dyspepsia had predia-
betes or diabetes; therefore, it seems that this group 
of patients should be screened for glucose metabolism 
disorders. High prevalence of GMD among patients 
with dyspepsia indicates potential benefits of perform-
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ing OGTT in this group of patients. Gastrointestinal 
symptoms may be an early manifestation of glucose 
metabolism disorders. There is a correlation between 
Helicobacter pylori infection and the presence of glu-
cose metabolism disorders.
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